Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

LA JOLLA P Form 4 April 18, 200	HARMACEUTI 6	CAL CO)									
FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSIO Washington, D.C. 20549							COMMISSION	OMB Number:	PROVAL 3235-0287 January 31,			
subject to STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF subject to Section 16. Section 16. SECURITIES Form 4 or Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, obligations Section 17(a) of the Public Utility Holding Company Act of 1935 or Section and company Act of 1940 Section 17(a) of the Investment Company Act of 1940								burden hou response	Estimated average burden hours per response 0.5			
See Instru- 1(b). (Print or Type R	esponses)								5. Relationship of	Reporting Per	son(s) to	
1. Name and Address of Reporting Person <u>*</u> SLOAN GAIL A			2. Issuer Name and Ticker or Trading Symbol LA JOLLA PHARMACEUTICAL CO [LJPC]						(Check all applicable)			
(Last) 6455 NANC	(First) (N Y RIDGE DRIV	/liddle) E	3. Date of (Month/D 04/17/20	ay/Year)	Trai	nsaction			Director X Officer (give below) V		Owner er (specify	
				If Amendment, Date Original led(Month/Day/Year)					 6. Individual or Joint/Group Filing(Check Applicable Line) _X_ Form filed by One Reporting Person Form filed by More than One Reporting Person 			
(City)	(State)	(Zip)	Table	e I - Non	-De	rivative S	Securi	ties Acq	uired, Disposed of	f, or Beneficial	ly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution any		3. Transac Code (Instr. 8 Code	3)	4. Securi n(A) or D (D) (Instr. 3, Amount	ispose	d of	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		
Common Stock	03/31/2006					156	A	\$ 3.06	3,652	D		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transacti Code (Instr. 8)	5. Number of orDerivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	Expiration Date		7. Title and Amount of Underlying Securities (Instr. 3 and 4)	
				Code V	(A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 4.46	04/17/2006		A	184,548	(2)	04/17/2016	Common Stock	184,548

Edgar Filing: LA JOLLA PHARMACEUTICAL CO - Form 4

Reporting Owners

Reporting Owner Name / Addres	ss	Relationships						
1.0.0	Director	10% Owner	Officer	Other				
SLOAN GAIL A 6455 NANCY RIDGE DRIV SAN DIEGO, CA 92121	Е		VP of Finance					
Signatures								
/s/ Gail A. Sloan	04/18/2006							

<u>**</u>Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Acquired pursuant to the Company?s Employee Stock Purchase Plan.

(2) The stock options vest and become exercisable monthly over the next three years.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.